UPDATE: Oppenheimer Starts PROLOR Biotech (PBTH) at Outperform; Opportunity in Therapeutic Proteins
Tweet Send to a FriendGet Alerts PBTH Hot Sheet
Price: $6.41 -0.31%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade PBTH Now!
(Updated - August 29, 2012 8:54 AM EDT)
Oppenheimer initiates coverage on PROLOR Biotech (NYSE: PBTH) with a Outperform. PT $7.00.
Analyst, Boris Peaker, said, "PROLOR is a biopharmaceutical company developing proprietary long-acting versions of already approved therapeutics. PROLOR's leading asset is hGH-CTP, a long-acting version of human growth hormone (HGH). A Phase III trial of hGH-CTP in adults is expected to start by year-end. We highlight that if approved, hGH-CTP would be the first long-acting HGH on the market. In addition, PROLOR has exclusive rights to CTP technology for all but four proteins. Merck (NYSE: MRK) developed and now sells a fertility drug using CTP modification, which we believe validates this technology. In our view, PROLOR remains still largely overlooked despite multiple 12-18 month catalysts."
For an analyst ratings summary and ratings history on PROLOR Biotech click here. For more ratings news on PROLOR Biotech click here.
Shares of PROLOR Biotech closed at $4.69 yesterday, with a 52 week range of $3.11-$6.69.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Oppenheimer initiates coverage on PROLOR Biotech (NYSE: PBTH) with a Outperform. PT $7.00.
Analyst, Boris Peaker, said, "PROLOR is a biopharmaceutical company developing proprietary long-acting versions of already approved therapeutics. PROLOR's leading asset is hGH-CTP, a long-acting version of human growth hormone (HGH). A Phase III trial of hGH-CTP in adults is expected to start by year-end. We highlight that if approved, hGH-CTP would be the first long-acting HGH on the market. In addition, PROLOR has exclusive rights to CTP technology for all but four proteins. Merck (NYSE: MRK) developed and now sells a fertility drug using CTP modification, which we believe validates this technology. In our view, PROLOR remains still largely overlooked despite multiple 12-18 month catalysts."
For an analyst ratings summary and ratings history on PROLOR Biotech click here. For more ratings news on PROLOR Biotech click here.
Shares of PROLOR Biotech closed at $4.69 yesterday, with a 52 week range of $3.11-$6.69.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts CEVA Inc. (CEVA) at Buy
- Topeka Capital Starts Cavium Networks (CAVM) at Hold
- BMO Capital Starts Gartner (IT) at Market Perform
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
